Janus Henderson Group PLC Has $119.72 Million Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Janus Henderson Group PLC decreased its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 26.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,296,077 shares of the biopharmaceutical company's stock after selling 465,484 shares during the period. Janus Henderson Group PLC owned approximately 0.10% of Gilead Sciences worth $119,717,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of GILD. HHM Wealth Advisors LLC boosted its stake in Gilead Sciences by 118.5% in the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock worth $26,000 after buying an additional 154 shares in the last quarter. YANKCOM Partnership purchased a new position in Gilead Sciences during the 4th quarter valued at $28,000. Decker Retirement Planning Inc. bought a new position in shares of Gilead Sciences during the fourth quarter valued at approximately $29,000. Crews Bank & Trust purchased a new stake in Gilead Sciences during the 4th quarter worth approximately $31,000. Finally, Stephens Consulting LLC increased its stake in shares of Gilead Sciences by 325.0% in the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company's stock valued at $31,000 after purchasing an additional 260 shares in the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction that occurred on Thursday, May 15th. The stock was sold at an average price of $99.82, for a total transaction of $249,550.00. Following the sale, the chief financial officer now directly owns 165,674 shares in the company, valued at $16,537,578.68. This represents a 1.49% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last three months, insiders have sold 25,429 shares of company stock worth $2,894,445. 0.27% of the stock is owned by insiders.

Gilead Sciences Stock Up 2.2%

Shares of GILD traded up $2.16 during midday trading on Friday, reaching $102.50. 6,395,303 shares of the stock were exchanged, compared to its average volume of 7,649,761. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. The company has a market capitalization of $127.63 billion, a P/E ratio of 277.03, a PEG ratio of 0.71 and a beta of 0.26. The company's 50 day moving average is $105.99 and its two-hundred day moving average is $99.58. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $119.96.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.77 by $0.04. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The company had revenue of $6.67 billion during the quarter, compared to analysts' expectations of $6.77 billion. During the same quarter last year, the firm earned ($1.32) earnings per share. The firm's quarterly revenue was down .3% compared to the same quarter last year. On average, sell-side analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be issued a $0.79 dividend. This represents a $3.16 annualized dividend and a dividend yield of 3.08%. The ex-dividend date is Friday, June 13th. Gilead Sciences's dividend payout ratio (DPR) is presently 66.53%.

Analyst Ratings Changes

GILD has been the subject of several research reports. Needham & Company LLC reiterated a "hold" rating on shares of Gilead Sciences in a research report on Friday, April 25th. Deutsche Bank Aktiengesellschaft raised Gilead Sciences from a "hold" rating to a "buy" rating and raised their price target for the stock from $80.00 to $120.00 in a report on Tuesday, February 18th. Morgan Stanley boosted their target price on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a report on Friday, April 25th. JPMorgan Chase & Co. raised their target price on Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a report on Thursday, March 27th. Finally, The Goldman Sachs Group increased their target price on Gilead Sciences from $85.00 to $96.00 and gave the stock a "neutral" rating in a report on Wednesday, February 12th. Nine equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $110.55.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.